Download Sample
Schedule a Meeting
NA : +1 804 441 9344
sales@towardshealthcare.com
June 2025
The worldwide peptide-based weight loss medication market is experiencing significant expansion, with projections indicating a revenue increase reaching several hundred million dollars by the end of the forecast period, spanning 2025 to 2034. This growth is driven by emerging trends and strong demand across key sectors.
Due to a growing obese population, there is a rise in the demand for the use of peptide-based weight loss medications. This, in turn, is driving their innovations, which are leading to collaborations among the companies. Their new candidates are being discovered and designed using AI. Their growing research and development, and manufacturing are increasing their adoption rates across different regions. This is increasing the opportunity for companies to launch their new or generic products in the market. Thus, this is promoting the market growth.
Peptide-based weight-loss medications market consists of therapeutic agents - primarily gut-hormone peptides or peptide-mimetics (GLP-1 receptor agonists, dual GLP-1/GIP agonists, amylin analogues, and related peptide combinations) - developed to reduce appetite, slow gastric emptying, improve metabolic control, and produce sustained body-weight loss. These drugs (injectables and emerging oral peptide/small-molecule GLP-1s) transformed obesity care in the 2020s by delivering clinically meaningful weight loss and broad cardiometabolic benefits; they are used for obesity and for overweight patients with comorbidities (and some remain indicated for type-2 diabetes). Major clinical success (e.g., semaglutide, tirzepatide) has driven rapid uptake, large revenue growth, and a crowded pipeline of next-generation peptide and non-peptide candidates.
Growth in Patient Volume: The number of patients with obesity is increasing. Additionally, there is a rise in the comorbidities associated with it. Thus, this is increasing the use of peptide-based weight loss medications.
Growing Innovations: There is a rise in the development of different types of peptide-based weight loss medications. Companies are also focusing on developing their various dosage forms for different routes of administration, such as injectables and oral formulations. This is leading to new collaborations among the companies to enhance their development and access.
For instance,
AI is being used for drug discovery in the peptide-based weight loss medication market. Different types of AI models are being developed for the optimization and generation of peptide sequences. It also helps in the optimization of their properties. The multifunctional peptides with desired actions can be developed using AI. AI also helps in discovering and understanding the drug receptor interactions and affinity. They are also being used in uncovering the new targets. AI models are also being used for developing new oral formulations with improved stability and bioavailability.
Increasing Awareness
There is a rise in awareness about obesity, which is increasing the demand for appropriate medications. This, in turn, is increasing the use of peptide-based weight loss medications. At the same time, the companies are increasing their development as well as conducting campaigns to increase awareness about these medications, which is enhancing the treatment uptake. Additionally, the healthcare centres are increasing their use for weight management as well to improve their comorbidities. Thus, this is driving the peptide-based weight loss medication market growth.
Expensive Medication
The peptide-based weight loss medications are expensive, which makes them unaffordable for patients. Additionally, the lack of insurance also contributes to the same. This, in turn, decreases the adherence of patients to the treatment. Thus, due to high cost, the use of peptide-based weight loss medications can be limited.
Why is Advancing Muscle-Preserving Weight Loss Medications an Opportunity in the Market?
To minimize the lean muscle loss, there is a rise in the development of muscle-preserving weight loss medications. These medications help in maintaining a healthy body composition and focus on minimizing body fat only. These actions are driven by the anabolic or anti-catabolic properties of the medication. Moreover, these advancements are enhancing the development of fat-burning or muscle growth-promoting medications. Additionally, the use of these medications will be enhanced in the geriatric population and athletes. Thus, the growing development of these medications is promoting the peptide-based weight loss medication market growth.
For instance,
By drug class/mechanism type, the GLP-1 receptor agonists segment held the largest share of the peptide-based weight loss medication market in 2024, due to its high efficiency. It helps in sustained weight management. Moreover, it was also used for diabetes. This increased its use, contributing to the market growth.
By drug class/mechanism type, the triple agonists (GLP-1/GIP/Glucagon) segment is expected to show the fastest growth rate during the upcoming years. It shows high efficiency due to its three metabolic pathways. This helps in reducing the weight to a greater extent. Furthermore, it does not affect the muscle mass and only reduces the fat.
By route of administration type, the injectable segment led the peptide-based weight loss medication market in 2024, as it showed increased bioavailability. Moreover, the stability of the peptide is protected as its chances of degradation are minimized. Additionally, they demonstrated fast and long-term action, which increased their acceptance rates.
By route of administration type, the oral peptides/small-molecule GLP-1s segment is expected to show the highest growth during the upcoming years. This route helps in enhancing the convenience of the patients. Additionally, they are preferred for chronic use. Their increased accessibility is also increasing patient adherence to the treatment.
By indication/use case type, the obesity/weight-management segment held the dominating share of the peptide-based weight loss medication market in 2024, because of its growing cases. This, in turn, increased the use of peptide-based weight loss medications. These drugs help in weight management and reduce the chances of further complications. This enhanced the market growth.
By indication/use case type, the overweight with cardiometabolic comorbidities segment is expected to show the fastest growth rate during the forthcoming years. This increased the use of peptide-based weight loss medications for weight management, which helps in improving or minimizing the comorbidities. Moreover, due to their improved efficacy and fast action, their use is increasing.
By distribution channel type, the prescription retail pharmacies & specialty clinics segment led the peptide-based weight loss medication market in 2024, driven by increased access. They also provided the patient with medical supervision and counselling. Moreover, the presence of insurance increases their adherence to the treatment.
By distribution channel type, the direct distribution/specialty pharmacies segment is expected to show the highest growth during the predicted time. They help in enhancing the distribution of the medication with controlled pricing and verification benefits. They also provide the distribution of temperature-sensitive drugs. Additionally, their telehealth integration is increasing accessibility.
By end user, the physicians/endocrinology & obesity clinics segment held the largest share of the global peptide-based weight loss medication market in 2024, due to the presence of specialized personnel. This increased the trust of the patients, enhancing the use of the medications. They also helped in the management of comorbidities along with weight management. This promoted the market growth.
By end user, the primary care segment is expected to show the fastest growth rate during the predicted time. They provide medications to a wide range of patients with obesity and comorbidities. Moreover, the growing awareness is increasing the visits to the primary care centers. Furthermore, the integration with telehealth is increasing their accessibility and patient convenience.
North America dominated the peptide-based weight loss medication market in 2024. The healthcare sector in North America is well developed, which contributed to the early adoption of the peptide-based weight loss medications. The presence of advanced industries significantly enhanced the development of these medications. Thus, this enhanced the market growth.
The development of the peptide-based weight loss medications, such as GLP-1 receptor agonists, in the U.S. is increasing. At the same time, their demand is also increasing due to the growing patients with obesity. This is increasing the R&D as well as their clinical trials. Moreover, with the growing investments and collaborations are accelerating their development is accelerating.
There is a growth in the use of peptide-based weight loss medications in Canada, as the healthcare systems are enhancing their access. Additionally, the growing health awareness and obese population are increasing their demand. The institutions are also conducting research and development to enhance their properties. These studies are further supported by the government funding.
Asia Pacific is expected to host the fastest-growing peptide-based weight loss medication market during the forecast period. Asia Pacific is experiencing a rise in obesity cases due to growing lifestyle changes. This is increasing the demand for peptide-based weight loss medications. The industries are expanding, which is increasing their manufacturing and innovations. Moreover, the government is providing investment and initiative to enhance its access. Thus, this is promoting the market growth.
To control appetite and energy metabolism by increasing or mimicking the action of naturally occurring gut hormones, and developing more potent and convenient, single, dual, or triple receptor agonists with improved efficacy is the focus for the R&D of peptide-based weight loss medication.
Key Players: Amgen, Novo Nordisk, Boehringer Ingelheim, Eli Lilly, Roche, Pfizer
The clinical trial of the peptide-based weight loss medication focuses on presenting the significant and sustained weight loss with safety, while the regulatory approvals focus on evidence from trials of the benefits of the medications with long-term cardiovascular safety.
Key Players: Novo Nordisk, Amgen, Eli Lilly, Rhythm Pharmaceuticals, Viking Therapeutics
To develop stable and sterile solutions for injectables or oral tablets with improved peptide protection from degradation and enhanced absorption in the bloodstream is the main criterion for formulation and final dosage preparation of peptide-based weight loss medication.
Key Players: Amgen, Novo Nordisk, Viking Therapeutics, Eli Lilly, Roche, Pfizer
In the patient support and service of peptide-based weight loss medication, the financial assistance, savings programs, educational resources, and guidance on nutrition and exercise are provided to the patients to enhance their treatment and manage its side effects.
Key Players: Novo Nordisk, Eli Lilly, WeightWatchers Clinic
In December 2024, after announcing the plans to launch Tirzepatide in the Indian market, the associate vice president and managing director of Eli Lilly (India), Vineet Gupta, stated that, due to growing disease burden of obesity, cancer, and diabetes, a growing population, and increasing health expenditure, a promising market is presented by India. Thus, the combination of these is providing an opportunity to the company. Hence, they will be launching their next line of innovations in India, which will be initiated by the launch of Tirzepatide and the obesity pipeline in 2025.
By Drug Class/Mechanism
By Route of Administration
By Indication/Use Case
By Distribution Channel
By End User
By Region
June 2025
May 2025